Tadocizumab
Based on 1 Customer Validation
Tadocizumab (C4G1; YM-337) is a humanized monoclonal antibody tageting integrin αIIbβ3. Tadocizumab has antiplatelet and antithrombotic effects, and can be used for cardiovascular disease research.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 97%
- CAS No.: 339086-80-5
- Masse moléculaire:47.619 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Fab-G1-kappa
Human
|
GPIIb/IIIa |
Tadocizumab (YM-337) significantly inhibits ex vivo ADP-induced platelet aggregation, and completely inhibits arachidonic acid-induced platelet aggregation[1].
Tadocizumab (YM-337) inhibits human platelet adhesion to von Willebrand factor, fibrinogen, fibronectin and subendothelial matrix[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Tadocizumab (YM-337; C4G1) at a dose of 1 mg/kg intravenous injection followed by 6 μg/kg/min infusion for 60 min prevented occlusive thrombus formation in monkeys, in a photochemically-induced thrombosis model in squirrel monkeys[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Fab-G1-kappa
ELISA, FACS, Functional assay
-
Loaded Tadocizumab on ProA biosensor, can bind Integrin alpha 2B beta 3 Protein, Human (HEK293, His, HY-P77716) with an affinity constant of 1.268E-08 M as determined in BLI assay.
Chemical Information
-
CAS No. 339086-80-5
-
Appearance Liquid
-
Masse moléculaire 47.619 kDa
-
Color Colorless to light yellow
-
SMILES
[Tadocizumab]
-
Synonyms
C4G1; YM-337
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
Fiche technique (258 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
[1]. S Kaku, et al. Antiplatelet and antithrombotic effects of YM337, the Fab fragment of a humanized anti-GPIIb/IIIa monoclonal antibody in monkeys. Thromb Haemost. 1996 Apr;75(4):679-84. [Content Brief]
[2]. Ken-ichi Suzuki, et al. Comparative studies of a humanized anti-glycoprotein IIb/IIIa monoclonal antibody, YM337, and abciximab on in vitro antiplatelet effect and binding properties. Biol Pharm Bull. 2002 Aug;25(8):1006-12. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Tadocizumab Related Classifications
HY-P99560 Related Classifications
Powered by Bioz